XML 135 R78.htm IDEA: XBRL DOCUMENT
v3.22.4

Contract revenues, Morphomer Tau small molecule - 2018 license agreement with Eli Lilly and Company (Details) SFr in Thousands |  |  | 3 Months Ended | 12 Months Ended | 42 Months Ended | 47 Months Ended
--- | --- | --- | --- | --- | --- | ---
Mar. 31, 2020 CHF (SFr) installment | Jan. 23, 2019 CHF (SFr) | Sep. 30, 2019 CHF (SFr) installment | Mar. 31, 2019 CHF (SFr) | Dec. 31, 2022 CHF (SFr) item | Dec. 31, 2021 CHF (SFr) | Dec. 31, 2020 CHF (SFr) | Dec. 31, 2022 CHF (SFr) | Dec. 31, 2022 CHF (SFr)
Contract revenues |  |  |  |  |  |  |  |  |
Revenue from contracts with customers |  |  |  |  | SFr 3,935 | SFr 0 | SFr 15,431 |  |
Deferred income |  |  |  |  | 587 | 717 |  | SFr 587 | SFr 587
2018 License Agreement with Eli Lilly and Company [Member] |  |  |  |  |  |  |  |  |
Contract revenues |  |  |  |  |  |  |  |  |
Revenue from contracts with customers |  |  |  |  | SFr 0 | 0 | 14,348 |  |
Morphomer Tau Small Molecule [Member] | 2018 License Agreement with Eli Lilly and Company [Member] |  |  |  |  |  |  |  |  |
Contract revenues |  |  |  |  |  |  |  |  |
Milestone payment received |  |  |  | SFr 80,000 |  |  |  |  |
Period to provide notice of termination of agreement |  |  |  |  | 3 months |  |  |  |
Number of representatives in joint steering committee by each party | item |  |  |  |  | 3 |  |  |  |
Revenue from contracts with customers |  |  |  |  | SFr 0 | SFr 0 | SFr 14,300 |  |
Deferred income |  |  |  |  | 0 |  |  | 0 | 0
Morphomer Tau Small Molecule [Member] | 2018 License Agreement with Eli Lilly and Company [Member] | Clinical and Regulatory [Member] |  |  |  |  |  |  |  |  |
Contract revenues |  |  |  |  |  |  |  |  |
Expected transaction price allocation |  |  |  |  | 880,000 |  |  | 880,000 | 880,000
Morphomer Tau Small Molecule [Member] | 2018 License Agreement with Eli Lilly and Company [Member] | Commercial [Member] |  |  |  |  |  |  |  |  |
Contract revenues |  |  |  |  |  |  |  |  |
Expected transaction price allocation |  |  |  |  | SFr 900,000 |  |  | 900,000 | 900,000
Morphomer Tau Small Molecule [Member] | 2018 License Agreement with Eli Lilly and Company [Member] | Research and Development [Member] |  |  |  |  |  |  |  |  |
Contract revenues |  |  |  |  |  |  |  |  |
Deferred research and development costs |  | SFr 6,900 |  |  |  |  |  |  |
Revenue from contracts with customers |  |  |  |  |  |  |  |  | SFr 6,900
Morphomer Tau Small Molecule [Member] | 2018 License Agreement with Eli Lilly and Company [Member] | Right-of-use License [Member] |  |  |  |  |  |  |  |  |
Contract revenues |  |  |  |  |  |  |  |  |
Revenue from contracts with customers |  | SFr 73,100 |  |  |  |  |  | SFr 40,000 |
Morphomer Tau Small Molecule [Member] | 2018 License Agreement with Eli Lilly, First Amendment [Member] |  |  |  |  |  |  |  |  |
Contract revenues |  |  |  |  |  |  |  |  |
Total potential collaboration agreement value |  |  | SFr 60,000 |  |  |  |  |  |
Number of installments | installment |  |  | 2 |  |  |  |  |  |
Morphomer Tau Small Molecule [Member] | 2018 License Agreement with Eli Lilly, First Amendment [Member] | Quarter 3, 2019 |  |  |  |  |  |  |  |  |
Contract revenues |  |  |  |  |  |  |  |  |
Milestone payment receivable |  |  | SFr 30,000 |  |  |  |  |  |
Morphomer Tau Small Molecule [Member] | 2018 License Agreement with Eli Lilly, First Amendment [Member] | March 31, 2020 |  |  |  |  |  |  |  |  |
Contract revenues |  |  |  |  |  |  |  |  |
Milestone payment receivable | SFr 30,000 |  | SFr 30,000 |  |  |  |  |  |
Morphomer Tau Small Molecule [Member] | 2018 License Agreement with Eli Lilly, Second Amendment [Member] |  |  |  |  |  |  |  |  |
Contract revenues |  |  |  |  |  |  |  |  |
Number of installments | installment | 2 |  |  |  |  |  |  |  |
Morphomer Tau Small Molecule [Member] | 2018 License Agreement with Eli Lilly, Second Amendment [Member] | March 31, 2020 |  |  |  |  |  |  |  |  |
Contract revenues |  |  |  |  |  |  |  |  |
Milestone payment receivable | SFr 10,000 |  |  |  |  |  |  |  |
Morphomer Tau Small Molecule [Member] | 2018 License Agreement with Eli Lilly, Second Amendment [Member] | Upon first patient dosed in a Phase 2 clinical study of a licensed product in the U.S. or EU. |  |  |  |  |  |  |  |  |
Contract revenues |  |  |  |  |  |  |  |  |
Milestone payment receivable | SFr 60,000 |  |  |  |  |  |  |  |

X
- Definition The number of installments for satisfying a milestone payment associated with a collaborative agreement. + References No definition available. + Details
Name: | aciu_CollaborativeAgreementMilestonePaymentNumberOfInstallments
Namespace Prefix: | aciu_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment(s) received for milestone payments associated with a collaborative agreement. + References No definition available. + Details
Name: | aciu_CollaborativeAgreementMilestonePaymentReceived
Namespace Prefix: | aciu_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Period of time that notice is required to be given for cancellation of the collaborative agreement contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod
Namespace Prefix: | aciu_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The total potential value of the collaborative agreement. + References No definition available. + Details
Name: | aciu_CollaborativeAgreementPotentialValue
Namespace Prefix: | aciu_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The number of representatives in a joint steering committee by each party as per the agreement. + References No definition available. + Details
Name: | aciu_NumberOfRepresentativesInJointSteeringCommitteeByEachParty
Namespace Prefix: | aciu_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of an entity’s right to consideration in exchange for goods or services that the entity has transferred to a customer, when that right is conditioned on something other than the passage of time (for example, the entity’s future performance). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2021-01-01 -Paragraph 105 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_105&doctype=Standard -URIDate 2021-03-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2021-01-01 -Paragraph 116 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_116_a&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_ContractAssets
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of current deferred income including current contract liabilities. [Refer: Deferred income including contract liabilities] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 55 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard -URIDate 2021-03-24 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 78 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of an entity’s right to consideration in exchange for goods or services that the entity has transferred to a customer that is unconditional. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2021-01-01 -Paragraph 105 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_105&doctype=Standard -URIDate 2021-03-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2021-01-01 -Paragraph 116 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_116_a&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_ReceivablesFromContractsWithCustomers
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2021-01-01 -Paragraph 113 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_113_a&doctype=Standard -URIDate 2021-03-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2021-01-01 -Paragraph 114 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_114&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_RevenueFromContractsWithCustomers
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2021-01-01 -Paragraph 120 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_120_a&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementWithLillyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=aciu_TauMorphomerSmallMoleculeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_PerformanceObligationsAxis=aciu_MilestonePaymentsClinicalAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_PerformanceObligationsAxis=aciu_MilestonePaymentsCommercialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_PerformanceObligationsAxis=aciu_ResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_PerformanceObligationsAxis=aciu_RightOfUseLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementWithLillyFirstAmendmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MaturityAxis=aciu_Quarter32019Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MaturityAxis=aciu_March312020Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementWithLillySecondAmendmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MaturityAxis=aciu_UponFirstPatientDosedInPhase2ClinicalStudyOfLicensedProductInU.s.OrEu.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |